Hansa Biopharma AB (publ) (STO:HNSA)

Hansa Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	354.42	405.28	732.06	1,496	651.34	1,139
Short-Term Investments	-	-	-	-	237.62	238.14
Cash & Short-Term Investments	354.42	405.28	732.06	1,496	888.96	1,378
Cash Growth	-49.73%	-44.64%	-51.07%	68.31%	-35.47%	129.17%
Accounts Receivable	181.32	144.97	78.03	42.96	9.71	0.11
Other Receivables	40.23	17.49	15.73	24.22	13.53	7.59
Receivables	221.55	162.46	93.76	67.18	23.24	7.7
Inventory	2.94	2.61	1.51	0.97	0.24	0.1
Prepaid Expenses	-	2.84	3.06	3.52	3.34	1.66
Other Current Assets	-	12.24	24.76	36.85	26.56	6.43
Total Current Assets	578.91	585.43	855.15	1,605	942.34	1,393
Property, Plant & Equipment	13.86	17.88	27.07	35.84	41.71	9.7
Other Intangible Assets	244.5	20.46	23.17	26.01	28.76	31.41
Long-Term Deferred Charges	-	176.88	112.65	20.85	-	-
Total Assets	837.27	800.64	1,018	1,687	1,013	1,434
Accounts Payable	56.16	37.62	86.97	62.48	53.36	26.67
Accrued Expenses	137.19	97.89	116.54	100.32	78.22	52.36
Current Portion of Long-Term Debt	141.47	-	-	-	-	-
Current Portion of Leases	8.06	7.68	7.5	7.17	6.89	4.42
Current Income Taxes Payable	2.1	2.71	1.6	0.6	-	0.13
Current Unearned Revenue	14.13	16.33	41.47	40.43	24.96	17.41
Other Current Liabilities	62.96	93.45	66.91	53.71	7.79	13.22
Total Current Liabilities	422.07	255.69	320.99	264.71	171.22	114.2
Long-Term Debt	753.64	1,065	844.9	762.6	-	-
Long-Term Leases	3.04	6.68	14.36	21.33	28.49	0.63
Long-Term Unearned Revenue	-	-	-	29.5	47.02	62.03
Long-Term Deferred Tax Liabilities	0.14	0.17	0.37	0.41	0.43	0.42
Other Long-Term Liabilities	99.44	63.3	5.3	5.95	8.08	15.09
Total Liabilities	1,278	1,390	1,186	1,084	255.24	192.37
Common Stock	-441.06	67.81	55.03	55.03	46.34	45.9
Additional Paid-In Capital	-	3,451	3,083	3,022	2,573	2,509
Retained Earnings	-	-4,110	-3,303	-2,471	-1,860	-1,312
Treasury Stock	-	-	-2.36	-2.59	-1.86	-1.42
Comprehensive Income & Other	-	0.94	-0.41	0.01	0.13	-0.14
Shareholders' Equity	-441.06	-589.83	-167.88	602.91	757.57	1,242
Total Liabilities & Equity	837.27	800.64	1,018	1,687	1,013	1,434
Total Debt	906.21	1,079	866.77	791.09	35.38	5.05
Net Cash (Debt)	-551.79	-673.73	-134.71	705.09	853.58	1,372
Net Cash Growth	-	-	-	-17.40%	-37.81%	131.98%
Net Cash Per Share	-8.07	-10.72	-2.56	15.70	19.19	32.54
Filing Date Shares Outstanding	84.76	67.81	52.67	52.44	44.47	44.47
Total Common Shares Outstanding	84.76	67.81	52.67	52.44	44.47	44.47
Working Capital	156.84	329.74	534.16	1,340	771.12	1,279
Book Value Per Share	-5.20	-8.70	-3.19	11.50	17.03	27.93
Tangible Book Value	-685.55	-610.29	-191.05	576.9	728.81	1,211
Tangible Book Value Per Share	-8.09	-9.00	-3.63	11.00	16.39	27.22

Source: S&P Global Market Intelligence. Standard template. Financial Sources.